3-Pyrrolidinecarboxylic Acid,5-Oxo-1-(Phenylmethyl)-,Methyl Ester

Continuous-flow catalytic hydrogenolysis of the N-benzyl protecting group in methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate has emerged as a critical enabler for the kilogram-scale synthesis of the antiepileptic drug brivaracetam. In this process, the compound undergoes regioselective enolate alkylation at the C-4 position prior to deprotection. Production-scale execution is governed by ICH Q7 Section 7.3 for intermediate handling and ICH Q3D for elemental impurities, with residual palladium controlled below 10 ppm when a 5% Pd/C (Johnson Matthey 5R 87L) catalyst is employed. The alkylation step uses 1.10–1.25 equivalents of 1-iodopropane freshly distilled over copper wire and is initiated by lithium diisopropylamide generated in situ at −70 °C to minimize β-hydride elimination and dialkylation. Once the alkylation is quenched and the intermediate extracted into methyl tert-butyl ether, the hydrogenolysis is performed in a loop reactor equipped with a metal membrane catalyst basket; the pressure is ramped from 2.0 bar to 4.5 bar H₂ at 55 °C while off-gas CO₂ content is monitored by mass flow spectroscopy to detect decarboxylation onset. Thermal runaway risk is mitigated by a 50 L Hastelloy C276 vessel with a jacket thermocouple interlock that halts hydrogen feed if the temperature exceeds 62 °C. After filtration through a 0.2 µm inline PTFE element, the crude 4-propylpyrrolidinone acid is saponified with 2.0 M NaOH at 40 °C and then coupled to (S)-2-aminobutanamide hydrochloride under EDC·HCl activation to furnish brivaracetam active pharmaceutical ingredient, which crystallizes as the levetiracetam congener meeting USP <661> specifications for container closure integrity.

How Does Reductive Amination of the Pyrrolidinone Core Yield 3-Aminopyrrolidine for Fluoroquinolone Libraries?

Reduction of the cyclic amide moiety in methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate provides access to 3-aminopyrrolidine, a key intermediate for the tosufloxacin series of antibacterials licensed in Japan. The compound is first converted to the corresponding carboxylic acid by treatment with 1.05 equivalents of aqueous LiOH in tetrahydrofuran/water (3:1 v/v) at 0–5 °C, followed by acidification and azeotropic drying with toluene. Subsequent activation with 1.2 eq isobutyl chloroformate and N-methylmorpholine at −10 °C followed by sodium borohydride reduction of the mixed anhydride yields the 3-hydroxymethyl derivative. Industry filings to the Pharmaceuticals and Medical Devices Agency typically reference JP XVI impurity control policies, requiring that 3-benzylaminopyrrolidine related substances be held below 0.15% w/w as measured by HPLC with a C18 5 µm 250×4.6 mm column using a phosphate-buffered methanol gradient. The N-benzyl group is next removed via transfer hydrogenation with 10% Pd(OH)₂/C and ammonium formate at 65 °C in methanol; this avoids the over-reduction of the pyrrolidine ring observed under high-pressure hydrogen conditions. After installation of a Boc protecting group with di-tert-butyl dicarbonate (1.15 eq) and conversion of the hydroxyl to a mesylate, the mesylate is displaced with benzylamine under reflux in acetonitrile for 18 hours. Catalytic hydrogenation of the secondary benzylamine over Pearlman’s catalyst at 3 bar furnishes the free 3-aminopyrrolidine, which is telescoped directly into a reaction with 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-chloro-4-oxoquinoline-3-carboxylic acid difluoroborate chelate to assemble the tosufloxacin core. The terminal product tosufloxacin tosilate is isolated as the monohydrate and must pass a Karl Fischer titration specification of 3.2–3.8% w/w water.

In asymmetric catalytic processes aimed at producing enantiomerically enriched metolachlor for agrochemical use, the chiral phosphoramidite ligand precursors derived from methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate have demonstrated turnover numbers exceeding 150,000 in the iridium-catalyzed imine hydrogenation step. The synthesis commences with a LiAlH₄ reduction of the ester in anhydrous diethyl ether at reflux; the resulting primary alcohol is treated with methanesulfonyl chloride (1.05 eq) and triethylamine in dichloromethane at 0 °C to generate the corresponding mesylate. Nucleophilic substitution with potassium diphenylphosphide, prepared from chlorodiphenylphosphine and potassium metal in boiling dioxane, affords a diphenylphosphinomethyl-substituted pyrrolidine intermediate with retention of the N-benzyl group. Coupling of this phosphine with bis(3,5-dimethylphenyl)phosphoryl azide in toluene at 90 °C forms the phosphoramidite ligand in situ. The plant-scale protocol, governed by the ISO 9001:2015 quality management system of the custom synthesis laboratory, stipulates a batch potency of 0.50–0.55 mol ligand per kilogram of reaction matrix when the Ir-(COD)-BArF pre-catalyst is activated under 6 bar H₂. The downstream fermentation-derived (R)-imine substrate is reduced to (S)-metolachlor with an enantiomeric excess consistently above 79%, the economic threshold defined in OECD Test Guideline 506 for chiral agrochemical active substances. The chiral ligand remains non-isolated in the process stream, which reduces the time of exposure to air-sensitive phosphine oxidation and meets the material durability requirements of 24-month on-site storage at −20 °C under argon.

Pyrrolidone-Based Latent Thermal Acid Generators in 193-nm Photoresist Formulations

When methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate is trans-esterified with perfluorobutanesulfonic acid in the presence of thionyl chloride and pyridine, the resulting sulfonate ester serves as a non-ionic photoacid generator (PAG) with a decomposition onset temperature of 168 °C as measured by differential scanning calorimetry at a ramp of 10 K/min under nitrogen. The compound is blended into acrylate-methacrylate copolymer-based photoresist vehicles at 2.0–3.5 wt% relative to total solids, with dissolution in propylene glycol monomethyl ether acetate (PGMEA, 99.8% electronic grade) to a final viscosity of 1.8–2.5 cP at 25 °C. Film-forming on 300 mm silicon wafers using a TEL CLEAN TRACK ACT 12 coater at 1,500 rpm yields a dry film thickness of 85 nm, which is pre-baked at 100 °C for 60 seconds before exposure with an ASML NXT:2050i scanner at a numerical aperture of 1.35. Post-exposure baking triggers a clean catalytic cascade releasing superacid, leading to deprotection of adamantyl methacrylate units in the resin. The developer used is 0.26 N tetramethylammonium hydroxide. Compliance with SEMI S2-0723 environmental health and safety guidelines and the RoHS 3 (EU 2015/863) annex II restrictions on perfluorinated alkyl substances is maintained because the PAG is bound into the cross-linked matrix during the post-anneal vitrification cycle, preventing leaching in downstream copper CMP effluents. The finalized patterned structure, with a critical dimension of 13 nm half-pitch, is transferred into hafnium oxide vertical NAND stacks by reactive ion etching in a CHF₃/O₂ plasma, confirming volatilization of the pyrrolidine-derived byproducts without re-deposition-induced surface roughness beyond 0.3 nm RMS as per AFM post-etch quality checks.

When the N-Benzyl Substituent Serves as a Leaving Group in 11C-Methylation Reactions

PET radiotracer production facilities exploit the facile hydrogenolysis reactivity of the N-benzyl group in methyl 1-benzyl-5-oxopyrrolidine-3-carboxylate to generate the free secondary amine, which is subsequently alkylated with no-carrier-added [¹¹C]methyl triflate. The entire synthesis is performed inside a GE TRACERlab FX C Pro automated synthesis module validated under 21 CFR Part 212 and EU GMP Annex 3 for radiopharmaceuticals. The precursor is prepared by treating the bulk intermediate with 1.0 mL of anisole and methanesulfonic acid (2.0 mL) at 80 °C in a microreactor coil of 0.5 mm internal diameter, which cleaves the benzyl and methyl ester in one step while minimizing racemization of the 3-chiral center. The resulting 5-oxopyrrolidine-3-carboxylic acid is loaded onto an Oasis WAX solid-phase extraction cartridge conditioned with 0.1% phosphoric acid in water. At the start of the run, cyclotron-produced [¹¹C]CO₂ is reduced to [¹¹C]CH₄ and converted to [¹¹C]CH₃OTf via gas-phase iodination at 720 °C followed by online silver triflate treatment. The methylating stream is passed through the SPE cartridge at 50 µL/min for 2.5 minutes; the stoichiometry is controlled by a mass flow controller calibrated to deliver 0.6–0.8 µmol of cold methyl triflate carrier to achieve a specific activity of 180–240 GBq/µmol. The product is purified on a semi-preparative HPLC column (Phenomenex Luna C18(2), 10 × 250 mm, 5 µm) with 9% ethanol in phosphate buffer at pH 4.2, eluting the N-[¹¹C]methyl-5-oxopyrrolidine-3-carboxylic acid tracer at 14.7 min. After sterile filtration through a 0.22 µm Millipore GV filter, the final formulation for injection meets Eur. Ph. monograph 2799 criteria for radionuclidic purity (> 99.9%) and radiochemical purity (> 98%) when analyzed by radio-TLC. The tracer is used in phase II clinical trials for imaging metabotropic glutamate receptor 5 expression in fragile X syndrome, with a typical administered dose of 250 MBq per subject.